T he spontaneously hypertensive rat (SHR) is one of the most widely used model of essential hypertension. Under special environmental conditions, the SHR develops disturbances of lipid and glucose metabolism. In addition, the SHR is predisposed to cardiac hypertrophy and fibrosis. Recently, we identified spontaneous mutation in Plzf (promyelocytic leukemia zinc finger) candidate gene for quantitative trait loci on chromosome 8 associated with blood pressure, cardiac hypertrophy, and fibrosis as well as with metabolic traits using congenic mapping in SHR, PD minimal congenic sublines, and sequence analyses. [1] [2] [3] [4] In particular, we found an intronic deletion in a putative Plzf enhancer associated with the downregulation of Plzf expression, amelioration of cardiac hypertrophy, fibrosis, and a modest decrease of blood pressure in the SHR.PD5 minimal congenic subline compared with SHR. 4 The Plzf gene was also prioritized because previous studies indicated its possible role in left ventricular hypertrophy and fibrosis. [5] [6] [7] In the current study, we generated a null Plzf allele in the SHR using transcription activator-like effector nuclease-mediated gene targeting in an attempt to replicate the previous congenic subline findings and to assess in vivo effects of Plzf on metabolic and cardiac traits. Our aim was to identify the cardiac hypertrophy/fibrosis and blood pressure quantitative trait loci and metabolic regulatory quantitative trait loci at the molecular level. Our results provide new evidence for a significant role of Plzf in the regulation of metabolic and cardiac traits in the SHR.
T he spontaneously hypertensive rat (SHR) is one of the most widely used model of essential hypertension. Under special environmental conditions, the SHR develops disturbances of lipid and glucose metabolism. In addition, the SHR is predisposed to cardiac hypertrophy and fibrosis. Recently, we identified spontaneous mutation in Plzf (promyelocytic leukemia zinc finger) candidate gene for quantitative trait loci on chromosome 8 associated with blood pressure, cardiac hypertrophy, and fibrosis as well as with metabolic traits using congenic mapping in SHR, PD minimal congenic sublines, and sequence analyses. [1] [2] [3] [4] In particular, we found an intronic deletion in a putative Plzf enhancer associated with the downregulation of Plzf expression, amelioration of cardiac hypertrophy, fibrosis, and a modest decrease of blood pressure in the SHR.PD5 minimal congenic subline compared with SHR. 4 The Plzf gene was also prioritized because previous studies indicated its possible role in left ventricular hypertrophy and fibrosis. [5] [6] [7] In the current study, we generated a null Plzf allele in the SHR using transcription activator-like effector nuclease-mediated gene targeting in an attempt to replicate the previous congenic subline findings and to assess in vivo effects of Plzf on metabolic and cardiac traits. Our aim was to identify the cardiac hypertrophy/fibrosis and blood pressure quantitative trait loci and metabolic regulatory quantitative trait loci at the molecular level. Our results provide new evidence for a significant role of Plzf in the regulation of metabolic and cardiac traits in the SHR.
Methods Animals
We targeted the Plzf gene by transcription activator-like effector nuclease method in a highly inbred strain of SHR/OlaIpcv. The SHR line with targeted Plzf gene was derived by microinjections of fertilized ova with pTAL438/439 constructs (see the next section). The Plzf mutant allele is semilethal because >95% of newborn homozygous animals die perinatally because of multiple developmental abnormalities. Heterozygous rats were morphologically normal and were used for metabolic, blood pressure, and cardiac phenotype analyses. For analysis of metabolic traits, we used 3-month-old SHR-Plzf +/− males (n=6) and age-matched wild-type SHR controls (n=6). Additional 2-month-old SHR-Plzf +/− males (n=8) and age-matched wild-type SHR controls (n=8) were used for blood pressure measurements. Blood pressures were measured for 4 weeks. Left ventricular hypertrophy and fibrosis were measured in additional 30-week-old SHR-Plzf +/− males (n=8) and age-matched wild-type SHR controls (n=8). All rats were housed in an air-conditioned animal facility and allowed free access to standard diet and water. All experiments were performed in agreement with the Animal Protection Law of the Czech Republic and were approved by the Ethics Committee of the Institute of Physiology, Czech Academy of Sciences, Prague.
Transcription Activator-Like Effector Nuclease Construction, Sequencing, and Genotyping SHR ova were microinjected with constructs pTAL438/439 coding for heterodimeric endonuclease that binds to target sequence in the first coding exon of the Plzf gene ( Figure S1 in the online-only Data Supplement). pTAL438 construct was targeting sequence 5′ GCA AGG CCA ATC AGA T 3′, followed by spacer 5′ GCG ACT GGC CGG GAC TTT GTG CG 3′ and by sequence 5′ CCA CCA TGA TGA CCA CAT 3′ recognized by pTAL439. pTAL438/439 constructs were assembled as described previously, 8 but cloned into the pCGoldyTALEN vector for expression. 9 We screened the pups using Surveyor (CelI) endonuclease (Transgenomics, Omaha, NE). We monitored cleavage of the polymerase chain reaction (PCR) product prepared with primers Plzf_ex2_26F: 5′ TCC AAC TGC AGA ACC CTA GC 3′ and Plzf_ex2_249R: 5′ GAT CTG CTG GAA GGT TTT CG 3′ using polyacrylamide gel electrophoresis. When we obtained evidence of Surveyor cleavage, we sequenced the PCR product both directly and after cloning into pCRII-Blunt-TOPO vector (Invitrogen, Carlsbad, CA) using BigDye Terminator v1.1 Cycle Sequencing Kit and ABI PRISM 310 Genetic Analyzer (Applied Biosystems, Foster City, CA). For genotyping the offspring of the founder, we took the advantage of the induced mutation (c.93delG) that resulted in the absence of a (CC's_GG) sequence recognized by the NciI restriction enzyme. Therefore, amplification of genomic DNA (primers were identical to those used for screening) with subsequent cleavage by NciI yielded 65-and 159-bp fragments for wild-type allele and 224-bp uncleaved product for the targeted allele, respectively.
Parameters of Glucose and Lipid Metabolism and Blood Pressure Measurements
The methods for assessment of skeletal muscle insulin sensitivity, glucose utilization in isolated white adipose tissue, tissue triglyceride and cholesterol measurements, all of the biochemical measurements in serum and tissues, and telemetric blood pressure measurements are described in the online-only Data Supplement.
Histomorphometric Analysis of the Heart
The methods for assessment of histomorphometric analysis of cardiac hypertrophy and fibrosis, including fractal analysis, are described in the online-only Data Supplement.
Gene Expression Profiling, Gene Expression Determined by Real-Time PCR, Allelic Expression of Plzf and Western Blotting
The methods for assessment of gene expression profiles in the liver, validation of gene expression in the liver and heart, allelic expression of Plzf and Western blotting analyses of protein expression are described in the online-only Data Supplement.
Statistical Analysis
The data are expressed as means±SEM. Individual groups were compared by unpaired Student t test. Normality of distribution was tested by Shapiro-Wilk method. The 24-hour mean values of systolic and diastolic blood pressures were analyzed by repeated measures of ANOVA with grouping effect of treatment and repeated measurements in time. Statistical significance was defined as P<0.05.
Gene expression data were preprocessed in Partek Genomic Suite 6.6 (Partek, Inc, Chesterfield, MO). Analyses were performed using methods similar to those described previously. 10 Briefly, the transcription profiles were background corrected using the RMA (robust multi-array average) method, probesets summarized by median polish, quantile normalized, and variance stabilized using base-2 logarithmic transformation. ANOVA yielded transcripts differentially expressed between analyzed samples (within LIMMA [linear models for microarrays]). 11 Storeys q values 12 were used to select significant differentially expressed genes (q<0.05). All statistical analyses were performed in R and within Bioconductor. 13 To identify significantly perturbed pathways, we performed Signaling Pathway Impact Analysis 14 on KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways: genes with P<0.05 were considered differentially transcribed. Where appropriate, the resulting statistical P values were corrected for multiple testing by FDR (false discovery rate) method. 15 Analysis of gene expression data was performed using the Relative Expression Software Tool (version REST 2009) that tests for significant differences by a randomization procedure. 16 
Results

Derivation of SHR With Targeted Plzf Gene
Of 43 animals born after microinjections, we detected a single male founder. Sequence analysis revealed a deletion of G at position 93 of the coding sequence (c.93delG; Figure S1 ) that resulted in a frameshift downstream glycine 31 (p.Gly31fs). The frameshift mutation caused the incorporation of 20 aberrant amino acids downstream of the deleted G, followed by a stop codon (not shown). We bred the founder with SHR to generate more heterozygous animals and intercrossed the heterozygotes to obtain homozygote knockouts. We monitored the breeding by PCR and NciI digestion (Methods). The Plzf −/− knockout on the SHR background is semilethal because >95% of Plzf −/− homozygotes died perinatally because of multiple developmental abnormalities. 17 In contrast, heterozygous Plzf +/− rats used in the current study were morphologically normal.
Parameters of Glucose and Lipid Metabolism
As can be seen in Table 1 , when compared with SHR wildtype controls, the SHR-Plzf +/− rats exhibited reduced body weight and relative weight of epididymal fat. In addition, the SHR-Plzf +/− heterozygotes showed lower serum and liver triglycerides, lower serum and liver cholesterol, levels of serum insulin, and glucose levels were similar to controls. Figure  1 demonstrates that SHR-Plzf +/− rats exhibited significantly increased sensitivity of adipose and muscle tissue to insulin action when compared with wild-type controls and were more tolerant to glucose during oral glucose tolerance test.
Cardiomyocyte Hypertrophy, Interstitial Fibrosis, and Blood Pressure
As can be seen in Figure 2 , the SHR-Plzf +/− heterozygous rats versus wild-type controls showed reduced cardiomyocyte hypertrophy and interstitial fibrosis and their left ventricular mass index was also significantly smaller (0.207±0.004 versus 0.244±0.008 mg/100 g body weight; P<0.001). The fractal analysis of the interstitial fibrosis revealed a lower complexity of the collagen network in the SHR-Plzf +/− rats (fD=1.159±0.03) versus SHR wild-type controls (fD=1.440±0.03; P<0.005). On the contrary, there was no reduction in the lacunarity estimates thus demonstrating no crucial change in the gappiness and extent of the collagen network ( Figure S2 ). We also found a significant inverse correlation between the complexity of the collagen network measured by fractal dimension and the lacunarity (r=0.70; P<0.005). There were no significant differences in systolic and diastolic blood pressures, and heart rates measured by telemetry (data no shown).
Gene Expression Profiles
Altogether, 1493 genes were differentially expressed at a nominal significance value of P<0.05. Importantly, we were able to confirm directional differences in expression of selected genes by real-time PCR analysis ( Figure S3 ). The GSEA (Gene-Set Enrichment Analysis)-based screening of the KEGG pathway database identified significantly lower or higher expression of genes from metabolic pathways, including genes that play important role in arachidonic acid metabolism (Alox12e, Cyp4f5, Cyp4a8, Ggt7, Pla2g5, and Pla2g12a), in arginine and proline metabolism (Asl, Got1, Gatm, Nos2, and Odc1), and in the PPAR signaling pathway (Table 2 ). In addition, SPIA (Signaling Pathway Impact Analysis) identified significant acute myeloid leukemia pathway and transcriptional misregulation in cancer pathway ( Table 2 ). Both these pathways contain deregulated genes with important role in cell cycle (Ccnd1 and Cdkn1a), insulin signaling (Foxo1, Hras, Mtor, Pik3cb, and Pik3r3), Wnt signaling (Tcf7l2), nuclear factor κB (Rel), and phosphatidylinositol 3-kinase-Akt signaling (Pik3r3, Mtor, Pik3cb, Foxo1, and Cdkn1a; Table 2 ). Plzf expression in SHR-Plzf +/− heterozygotes appeared increased in comparison to wildtype controls both in microarray experiment in the liver and as detected by RT PCR in the heart with primers that amplified PCR products of both mutant and wild-type Plzf alleles ( Figure 3 ; Table 2 ). However, the increase was because of biallelic Plzf expression. Moreover, wild-type allele expression was only 33%, which translated into reduced wild-type (functional) Plzf mRNA expression in SHR-Plzf +/− heterozygotes versus SHR controls by 51% (Figure 3) . Reduced functional mRNA expression led to lower PLZF (promyelocytic leukemia zinc finger) protein expression in heart, liver, Figure 4 shows the cardiac expression of genes selected from pathways identified by the gene expression profiling in the liver. We selected genes that might play important role in the pathogenesis of cardiac hypertrophy and fibrosis. As can be seen, amelioration of cardiac hypertrophy and interstitial fibrosis in SHR-Plzf +/− heterozygotes versus SHR controls was associated with reduced expression of Ccnd1 (cyclin D1) gene, whereas the expression of Cdkn1a (cyclin-dependent kinase inhibitor 1A), Foxo1 (forkhead box O1), and Nos2 (nitric oxide synthase 2) genes was significantly increased. We were able to validate most of these differences at the protein level except for the Nos2 where we observed reduced level of NOS2 protein in the heart of SHR-Plzf +/− heterozygotes ( Figure S4 )
Differentially Expressed Genes and Proteins in the Heart
Discussion
In the current study, we found that reduced expression of wild-type Plzf in heterozygous SHR-Plzf +/− animals versus SHR controls was associated with amelioration of several parameters of lipid and glucose metabolism including lower adiposity, reduced serum and hepatic triglycerides and cholesterol, and increased sensitivity of adipose and muscle tissue to insulin action. These results provide compelling evidence that Plzf plays an important role in regulation of lipid and glucose metabolism. In addition, we found that heterozygous SHR-Plzf +/− animals, compared with SHR wild-type controls, exhibited amelioration of cardiomyocyte hypertrophy and fibrosis, which was independent of blood pressure. Quantitative reduction of interstitial fibrosis in heterozygous SHR-Plzf +/− rats was coupled with a decrease in the complexity of the collagen network and a well-preserved, homogeneous general architecture given by the comparable result in the lacunarity trait. This finding is in agreement with previously published fractal analyses in hypertensive mice showing that collagen associated with reparative fibrosis was highly disorganized and more space filling. 18, 19 Replacement of cardiomyocytes by disordered collagen fibers may contribute to the myocardium pathology. Altogether, these metabolic ↑Cyp71a, ↑Acer2, ↓Csgalnact1, ↑Ido2, ↑Cyp4a8, ↑Cyp3a9, ↑Agpat4, ↑Upp2, ↑Hsd17b2, ↓Pdxk, ↓Dnmt1, ↑Gpt2, ↑Got1, ↑Pla2g12a, ↓B3gnt2, ↑Sgms1, ↑Ddc, ↓Gbe1, ↑Pole3, ↓Gale, ↑Cyb8b1, ↑Cd38, ↓Me1, ↑Asl, ↑Galnt6, ↓Gatm, ↓Mpi, ↓Atp6v1a, ↑Ugp2, ↑Polg2, ↓Idh3, ↑Pla2g5, ↑Pold1, ↓Uck2, ↑Sds, ↑Nadufb5, ↓Me3, ↓Odc1, ↑Nos2, ↑B4galnt1, ↑Pola2, ↓Inpp1, ↓Sgms2, ↑Ears2, ↑Dgke, ↑Cds2, ↑Ggt7, ↑H6pd, ↑Dhrs3, ↓Ndst3, ↑Abo, ↑Hsd3b6, Pi4kb, ↑Cyp4f5, ↑Alox12e, ↑Hpse PPAR signaling pathway <0.05 ↑Cyp7a1, ↑Cyp4a8, ↓Scd1, ↑Cyp8b1, ↓Me1, ↑Scd, ↑Cpt1c, ↓Fabp7, ↓Fabp2, ↑Ppara SPIA on KEGG pathway (deregulated) pGFWER_Q (SPIA) Deregulated genes (P<0.05)
Acute myeloid leukemia <0.005 ↑Plzf*, ↓Pik3r3, ↓Ccnd1, ↑Hras, ↓Mtor, ↑Tcf7l2, ↓Pik3cb
Transcriptional misregulation in cancer <0.05 ↑Plzf*, ↑Foxo1, ↓Rel, ↓Atf1, ↑Itgam, ↑Pax5, ↑Flt1, ↑Cd40, ↓Kdm6a, ↓Hpgd, ↑Cdkn1a (=p21), ↓Id2, ↓Pbx1, ↓Cdk9
↑ indicates higher expression in SHR-Plzf +/− vs spontaneously hypertensive rat; ↓, lower expression in SHR-Plzf +/− vs spontaneously hypertensive rat; FDR, false discovery rate; GSEA, Gene-Set Enrichment Analysis; PPAR, peroxisome proliferator-activated receptor; SPIA, Signaling Pathway Impact Analysis; and pGFWER_Q, Family-wise error rate of global P value.
*Biallelic expression of Plzf (mutant+wild-type).
and cardiac findings in SHR-Plzf +/− rats are consistent with results obtained in SHR.PD5 minimal congenic subline 1, 4 and provide evidence that mutant Plzf is the quantitative trait gene. On the contrary, radiotelemetry data did not demonstrate significant effects of reduced expression of PLZF on blood pressure in SHR-Plzf +/− rats. It is possible that effects on blood pressure would be present in homozygous SHRPlzf −/− animals if they were viable. It has been previously demonstrated that Plzf knockout mice were resistant to angiotensin-induced cardiac hypertrophy and fibrosis. 5 In addition, it has been suggested that direct interaction of the Plzf with AT 2 angiotensin receptor induces expression of phosphatidylinositol-3 kinase p85α subunit, which promotes protein synthesis. This pathway may explain missing cardiac hypertrophic response in mice deficient in AT 2 .
6,7 Furthermore, direct interaction of Plzf with (pro)renin receptor leads to increased expression of p85α phosphatidylinositol-3 kinase, the same target as in the AT 2 cascade. The (P)RR seems to play a key role in cardiovascular end-organ damage, insulin sensitivity, and adiposity. 20, 21 In the current study, we observed in SHR-Plzf +/− rats reduced expression of Pik3r3 and Pik3cb genes that code for regulatory and catalytic subunits of phosphoinositide 3-kinase, respectively. It is therefore possible that amelioration of cardiac hypertrophy and fibrosis is associated with reduced PI3K.
To search for molecular mechanisms that are responsible for regulation of metabolic and cardiac traits, we analyzed gene expression profiles in livers isolated from SHR-Plzf +/− heterozygous rats and wild-type SHR controls. We observed that reduced expression of wild-type Plzf in heterozygous rats was associated with deregulation of genes from arachidonic acid and arginine and proline metabolic pathways and PPAR signaling pathway. These pathways are involved mainly in inflammatory processes (metabolites of arachidonic acid) and lipid metabolism (Scd1, a key gene for fatty acid metabolism was downregulated in heterozygous rats).
In addition, Signaling Pathway Impact Analysis revealed several deregulated genes that play important role in cell cycle, insulin signaling, Wnt signaling, nuclear factor kappa B signaling, and phosphatidylinositol 3-kinase-Akt signaling pathway. Regulators of cell cycle are activated even in nonproliferating cells and cause increased lipid synthesis, decreased oxidative metabolism, and increased glycolytic metabolism. 22 Cyclin D1 (Ccnd1) is one of genes that showed reduced expression in SHR-Plzf +/− rats. Recently, a novel function of cyclin D1 was discovered when it was shown that cyclin D1 represses gluconeogenesis and oxidative phosphorylation by inhibiting peroxisome proliferator-activated receptor γ coactivator-1α activity in a CDK4-dependent manner. 23 Mice with targeted cyclin D1 specifically in the liver exhibited increased gluconeogenesis and hyperglycemia. 24 Interestingly, it was demonstrated that Cdkn1b (p27) and Cdkn1a (p21) are important regulators of adipogenesis. Furthermore, combined deletion of p27 and p21 was associated with an increase in adipocyte number and obesity, hypercholesterolemia, glucose intolerance, and insulin insensitivity. 25 In the current study, increased expression of Cdnk1a was associated with reduced adiposity in SHR-Plzf +/− rats. FoxO1 has been reported to regulate hepatic gluconeogenesis [26] [27] [28] and also the expression of Ccnd1 at the transcription level. 29 Recently, TCF7L2 has been genetically linked to diabetes mellitus, and several human single-nucleotide polymorphisms have been identified within the TCF7L2 gene and correlate with increased incidence of diabetes mellitus.
30
TCF7L2 is a transcriptional repressor of hepatic glucose metabolism. In postprandial state, increased TCF7L2 inhibits binding of CREB (cAMP responsive element binding protein) and FoxO1 to the gluconeogenic promoters. TCF7L2 thus plays a critical role in the regulation of gluconeogenesis. 31 Liver expression of Tcf7l2 was increased in SHR-Plzf and SHR males. PLZF expression in tissues from one surviving SHR-Plzf −/− homozygote (-/-) was also measured. Theoretical molecular weight of unmodified PLZF is 74 kDa. We observed signal consistently at slightly >80 kDa; in skeletal muscle, there can also be a genuine minor isoform of ≈60 kDa (absent in null homozygotes and downregulated in heterozygotes; C, bottom). In liver, kidney, and heart, there is a cross-reacting protein of ≈100 kDa, which most probably does not represent a PLZF isoform because there is no evidence in mammalian genomes/ transcriptomes of such larger coding sequence. mice where Plzf knockdown was associated with ameliorated glucose homeostasis. 32 D type cyclins play an important role in regulating proliferation of cardiomyocytes during embryonic development, but their expression is reduced postnatally and postnatal growth of cardiomyocytes is hypertrophic since the ability of mammalian cardiomyocytes to divide ceases shortly after the birth. On the contrary, in pathological cardiac hypertrophy, expression of cyclins and cyclin-dependent kinases is upregulated. 33 In the current study, we observed reduced abundance of Ccnd1 transcript and protein and increased expression of Cdkn1a gene and protein in the heart of SHR-Plzf +/− heterozygous rats, which was associated with amelioration of left ventricular hypertrophy. Congruently, cardiac hypertrophy induced by aortic constriction in rats was associated with reduced expression of Cdkn1a. 34 Cyclin D1 has been shown to be a downstream target of Wnt signaling including Foxo1 gene. 35 In addition, we found reduced expression of NOS2 protein in the heart of SHR-Plzf +/− heterozygous rats despite the fact that the Nos2 transcript was increased. It has been reported that mice with myocardial NOS2 overexpression are predisposed to cardiac fibrosis, cardiomyocyte death, and cardiac hypertrophy. 36 Genome-wide association studies did not reveal singlenucleotide polymorphisms within PLZF gene associated with left ventricular hypertrophy, blood pressure, or metabolic traits. However, a study by Arnett et al. 37 reported associations with single-nucleotide polymorphisms within NCAM gene that is closely linked to PLZF in humans. Thus, it is possible that because of linkage disequilibrium PLZF variants could be responsible for left ventricular hypertrophy in this genomewide association studies. In summary, reduced expression of wild-type Plzf in SHRPlzf +/− heterozygotes versus SHR controls is associated with significantly reduced adiposity, hepatic steatosis, increased glucose tolerance, sensitivity of adipose and muscle tissue to insulin action, reduced cardiac hypertrophy, and fibrosis. Gene expression profiles in liver and expression of selected genes in the heart revealed deregulated genes in metabolic pathways, PPAR signaling, and cell cycle regulation. These results provide evidence for the role of Plzf in the regulation of metabolic and cardiac traits in the rat and suggest a cross talk between cell cycle regulators, metabolism, cardiac hypertrophy, and fibrosis.
Perspectives
The results of the current studies are consistent with the hypothesis that increased expression of Plzf in the SHR versus SHR-Plzf +/− rats predisposes to metabolic disturbances, cardiac hypertrophy, and fibrosis. Accordingly, these findings indicate a possible role of Plzf in the pathogenesis of insulin resistance, abdominal obesity, cardiac hypertrophy, and fibrosis. Our study is expected to motivate further studies to decipher the role Plzf variants and related genes in the risk for metabolic syndrome, diabetes mellitus, and cardiovascular disease. 
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